The EMA issued a revised guideline Monday on evaluating antibacterial drugs to better align data requirements for clinical trials. The revision reflects extensive discussions among regulators in the EU, Japan and the U.S. to help sponsors of the drugs design clinical trials that meet the evidence needs of multiple regulatory agencies.